MetaCap

Eikon Therapeutics (EIKN) vs SAB Biotherapeutics (SABS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Eikon Therapeutics is the larger company by market cap ($256.8 million vs $253.1 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

EIKN-68.40%SABS-29.40%
+20%-27%-73%
Feb 5, 20261 yearNov 20, 2026
EIKN-67.31%SABS-32.61%
+7%-32%-71%
Feb 2, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

EIKN versus SABS key metrics
MetricEIKNSABS
Share price$4.74$2.81
Market cap$256.84M$253.15M
1-day change-0.42%-3.44%
YTD return—-24.87%
1-year return—-28.86%
5-year return—-97.32%
EPS (TTM)$-7.86$-1.35
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Revenue growth (YoY)—-100.00%
Net income (latest FY)—$13.27M
52-week high$17.40$5.15
52-week low$4.72$2.44
Distance from 52-week high-72.76%-45.44%
Analyst consensusbuystrong_buy
Avg. price target upside+406.33%+314.23%
Average volume560.40K633.60K
Shares outstanding54.19M90.09M
Employees38486
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Eikon Therapeutics

EIKN stock →

Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 384 employees

About SAB Biotherapeutics

SABS stock →

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 86 employees

EIKN vs SABS FAQ

Which is bigger, Eikon Therapeutics or SAB Biotherapeutics?

Eikon Therapeutics (EIKN) is larger, with a market capitalization of $256.84M compared with $253.15M for SAB Biotherapeutics (SABS).

Are Eikon Therapeutics and SAB Biotherapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons